Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone650-641-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$108.47 million
Profitability
Miscellaneous
Employees393
Next Earnings Date11/4/2019 (Estimated)
OptionableOptionable
Intersect ENT (NASDAQ:XENT) Frequently Asked Questions
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT Inc (NASDAQ:XENT) issued its quarterly earnings results on Thursday, August, 1st. The medical equipment provider reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.02. The medical equipment provider earned $26.66 million during the quarter, compared to analyst estimates of $27.13 million. Intersect ENT had a negative net margin of 31.43% and a negative return on equity of 29.16%. The business's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.14) EPS. View Intersect ENT's Earnings History.
When is Intersect ENT's next earnings date?
What guidance has Intersect ENT issued on next quarter's earnings?
Intersect ENT updated its FY 2019 earnings guidance on Thursday, August, 1st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $108.5-108.5 million, compared to the consensus revenue estimate of $114.84 million.
What price target have analysts set for XENT?
8 analysts have issued 12-month price targets for Intersect ENT's stock. Their forecasts range from $17.00 to $40.00. On average, they anticipate Intersect ENT's stock price to reach $26.46 in the next twelve months. This suggests a possible upside of 52.6% from the stock's current price. View Analyst Price Targets for Intersect ENT.
What is the consensus analysts' recommendation for Intersect ENT?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intersect ENT.
What are Wall Street analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. Northland Securities analysts commented, "We are upgrading Intersect ENT to a Market Perform rating. We had downgraded the stock immediately after the Q1 report. The stock has reached our price target, hence the ratings change. We note though, the ratings change does not reflect a fundamental change in outlook, at least for now." (7/10/2019)
- 2. According to Zacks Investment Research, "Over the past year, shares of Intersect ENT have underperformed the industry it belongs to. Escalating costs and expenses continue to weigh on the company’s margins. This apart, the pricing scenario is persistently tough for Intersect ENT. Strong competitors in the large medical device market also pose a tough challenge. On a positive note, within a short span of time, the SINUVA line of business has made a considerable progress with market access and field force balance. Within the company’s Propel line, Intersect ENT registered 10% growth in the top line during the fourth quarter 2018, driven by an expanded usage of Contour among both the current as well as the new physicians." (5/3/2019)
- 3. BTIG Research analysts commented, "Intersect reported Q4 revenue in line with its preannouncement. Guidance of $123M-$127M (also given previously) remains just below the Street’s $127.2M but not surprising given some conservatism early in the year. The company will no longer guide SINUVA but is aware of Street estimates and will see how sales play out. The big surprise was operating expense guidance of $135-137M which was well above most estimates. We think shares will be pressured Tuesday. While a good portion of this increased spend will be R&D for a new drug-coated balloon, it is also clear that much of XENT’s growth is coming through head count. While Intersect will have significantly more data coming, we continue to remain cautious around reimbursement for SINUVA. We do not know what will happen with the re- proposed J-Code and we are not sure how many insurance companies will decide to pay more than once per year." (2/26/2019)
Has Intersect ENT been receiving favorable news coverage?
News stories about XENT stock have been trending neutral on Tuesday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Intersect ENT earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Intersect ENT.
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Inspire Medical Systems (INSP), Silk Road Medical (SILK), AtriCure (ATRC), Orthofix Medical (OFIX), Luminex (LMNX), Cryolife (CRY), Shockwave Medical (SWAV), Tactile Systems Technology (TCMD), Anika Therapeutics (ANIK), Cerus (CERS) and LeMaitre Vascular (LMAT).
What other stocks do shareholders of Intersect ENT own?
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 49)
- Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 61)
- Mr. David A. Lehman, Gen. Counsel & Sec. (Age 58)
- Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 55)
- Ms. Christine R. Kowalski, Chief Operations Officer (Age 62)
How do I buy shares of Intersect ENT?
Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of XENT stock can currently be purchased for approximately $17.34.
How big of a company is Intersect ENT?
Intersect ENT has a market capitalization of $545.74 million and generates $108.47 million in revenue each year. The medical equipment provider earns $-22,920,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Intersect ENT employs 393 workers across the globe.View Additional Information About Intersect ENT.
What is Intersect ENT's official website?
How can I contact Intersect ENT?
Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]
MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
